Insulin Resistance & Age-Related Macular Degeneration (AMD)

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as AMD. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest significant retinal damage until their 60s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.91) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.91 means that 91% of the rise in AMD over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

Insulin Resistance Questionnaire →

The mechanistic pathway — how insulin resistance damages the retina: Insulin resistance triggers four converging pathways that degrade macular tissue. 1. VEGF overexpression: Chronic hyperinsulinaemia stimulates Vascular Endothelial Growth Factor (VEGF) via the PI3K/Akt pathway — driving the choroidal neovascularisation that defines wet AMD. 2. Systemic inflammation: Elevated TNF-α, IL-6, and IL-1β dysregulate the complement pathway (particularly Complement Factor H (CFH)), accelerating Retinal Pigment Epithelium (RPE) degeneration and drusen formation — the hallmark of dry AMD. 3. AGE accumulation: Glucose reacting with proteins forms advanced glycation end-products that thicken Bruch's membrane, impairing nutrient exchange between the choroid and RPE — one of the earliest structural changes in AMD. 4. Retinal insulin signalling failure: Insulin receptors on photoreceptors and Müller glia govern cell survival and VEGF regulation; when systemic IR impairs this signalling, photoreceptor degeneration accelerates independently of blood glucose levels. This is not a coincidental association — it is a multi-pathway causal sequence independently documented across multiple research groups. Sources: Kaarniranta et al. (2020); Roddy et al. (2020); Colijn et al. (2017); Chiu et al. (2007).

Why AMD is not simply a consequence of ageing: AMD's dramatic rise since the 1970s mirrors the rise in insulin resistance with exceptional statistical precision in both countries. Ageing alone cannot explain the epidemiological trend — the proportion of older adults has not risen remotely as fast as AMD prevalence. The metabolic model provides a coherent explanation: AMD is, in significant measure, a consequence of metabolic ageing driven by chronic insulin resistance. Reversing insulin resistance through very low carbohydrate diet with no grains, intermittent fasting and, if suitable a GAPS gut addresses all four mechanistic pathways, offering a rational evidence-aligned strategy for slowing AMD progression and protecting residual vision — in addition to or in place of conventional anti-VEGF injection therapy.

The stage of AMD matters. In early to intermediate dry AMD, removing the metabolic stimulus through VLC diet and intermittent fasting can realistically halt progression and may reduce drusen burden over time as RPE autophagy is restored. In later-stage AMD where photoreceptor and RPE tissue has already been lost, that structural damage is permanent — but intervention still protects remaining vision and addresses the systemic IR that is simultaneously driving other conditions. This is one reason early HOMA-IR testing in the 40s and 50s is so clinically significant: AMD is far more tractable before structural loss has occurred.

Data sources

Many people with this condition have at least one other insulin-resistance-driven condition. See the full picture — all 10 conditions, their r values, prevalence data, and 50-year rise figures in one place:  See all 10 conditions →

← Return to Start Your Remission Here